medigraphic.com

2020, Number 2

<< Back Next >>

Rev Mex Anest 2020; 43 (2)

Coronavirus-2019. General considerations

Sánchez-Zúñiga MJ, Carrillo-Esper R

Language: Spanish
References: 20
Page: 83-91
PDF size: 451.51 Kb.


ABSTRACT

According to what was published by the WHO (World Health Organization), a first case of acute respiratory infection, of unknown origin, appeared in the province of HUBEI, CHINA, in the city of WUHAN, (December 2019). After having ruled out other etiological agents, the isolation of a new coronavirus (7-01-2020) was achieved, which was called new coronavirus (nCOV, COVID-19), currently named SARS-CoV-2. Coronaviruses, being important pathogens, can infect the respiratory, gastrointestinal, hepatic, and nervous systems of humans and birds, livestock, bats, mice, and other wild animals. Since the outbreaks of SARS (Severe Acute Respiratory Syndrome) in 2002 and MERS (Middle East Respiratory Syndrome) in 2012, the transmission of these viruses between humans and animals has been demonstrated.


REFERENCES

  1. World Health Organization Press Conference. The World Health Organization (WHO) Has Officially Named the Disease Caused by the Novel Coronavirus as COVID-19. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

  2. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12. doi: 10.3390/v12040372.

  3. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27:325-328.

  4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395:565-574.

  5. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020. China CDC Weekly. (Accessed February 20, 2020). Available in: http://weekly. chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51.

  6. Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect. 2020;9:313-319. doi: 10.1080/22221751.2020.1725399.

  7. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181-192. doi: 10.1038/s41579-018-0118-9.

  8. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242.

  9. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364-374.

  10. Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond). 2020;134:543-545.

  11. Bavishi C, Maddox TM, Messerli FH. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. JAMA Cardiol. 2020. doi: 10.1001/jamacardio.2020.1282. [Epub ahead of print].

  12. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454.

  13. Lineamiento estandarizado para la vigilancia epidemiológica y por laboratorio de COVID-19. Disponible en: https://www.gob.mx/salud/documentos/nuevo-coronavirus.

  14. Wujtewicz MA, Dylczyk-Sommer A, Aszkiełowicz A, Zdanowski S, Piwowarczyk S, Owczuk. COVID-19-what should anaethesiologists and intensivists know about it? Anaesthesiol Intensive Ther. 2020;52:1-18.

  15. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;28:1-34. doi: 10.1007/s00134-020-06022-5. Epub ahead of print. PMID: 32222812; PMCID: PMC7101866.

  16. Arabi YM, Murthy S, Webb S. Correction to: COVID-19: a novel coronavirus and a novel challenge for critical care [published online ahead of print, 2020 Mar 18]. Intensive Care Med. 2020;46:1-2. doi: 10.1007/s00134-020-06009-2.

  17. Bouadma L, Lescure FK, Lucet JC, Yazdanpanah Y, Timsit JF. Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists Intensive Care Med. 2020;46:579-582.

  18. McCloskey B, Heymann DL. SARS to novel coronavirus: old lessons and new lessons. Epidemiol Infect. 2020; 148: e22. doi: 10.1017/S0950268820000254.

  19. Peng QY, Wang XT, Zhang LN. Chinese Critical Care Ultrasound Study Group (CCUSG). Findings of lung ultrasonography of novel corona virus pneumonia during the 2019–2020 epidemic. Intensive Care Med https://doi.org/10.1007/s00134-020-05996-6.

  20. Zhang W. Imaging changes in severe COVID-19 pneumonia. Intensive Care Med. 2020;46:583-585. https://doi.org/10.1007/s00134-020-05976-w.




2020     |     www.medigraphic.com